<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Accelerate ADC Development

Advance your biologics pipeline with organoid and PDX platforms, supported by binding, ADCC, and bystander killing assays.

Explore ADC Services
Contact Our ADC Team
End-to-End Services

Comprehensive ADC Development

Crown Bioscience delivers end-to-end support for antibody-drug conjugate (ADC) development. Our integrated approach combines patient-derived organoids (PDOs), patient-derived xenograft (PDX) models, and functional assays to accelerate candidate selection and improve translational relevance. With expertise spanning binding assays, ADCC, and bystander killing, we provide the industry’s most comprehensive CRO solutions for ADCs and next-generation biologics.

 
Organoids
Organoids
Organoids for ADCs

Patient-derived organoids provide predictive in vitro models for ADC testing, enabling biomarker-driven insights and clinically relevant results.

Learn More
PDX Models
PDX Models
PDX for ADCs

Crown Bioscience’s expansive PDX collection offers translational in vivo systems to evaluate ADC efficacy, durability, and tumor-specific targeting.

Learn More
card-binding
Functional Assays
Assays for ADCs

From binding assays to ADCC and bystander killing, our assay suite enables deep mechanism-of-action evaluation across organoid and PDX platforms.

View Assays

Frequently Asked Questions

Why use organoids in ADC development?

Organoids preserve patient tumor heterogeneity, enabling predictive ADC testing and biomarker-driven insights.

How do PDX models support ADC research?

PDX models provide in vivo validation for ADC efficacy, safety, and durability in clinically relevant settings.

What functional assays are available for ADC development?

We offer binding assays, ADCC testing, and bystander killing assays across organoid and PDX models.

What makes Crown Bioscience the best CRO for ADCs?

Our unmatched organoid and PDX collections, combined with translational assays, provide end-to-end ADC development services.

What is phage display antibody discovery?

Phage display is a technology used to rapidly identify high-affinity antibodies by screening a diverse library of candidates. It helps in selecting developable antibodies for targeted therapies, including ADCs.

How do you characterize antibodies for ADC development?

We conduct in vitro profiling, including target binding and off-target assessments, and evaluate developability factors such as stability and aggregation to ensure the best candidates for ADC generation.

What functional assays are available for ADC validation?

We provide target binding and internalization studies, tumor cell killing potency assays, and bystander killing assays, and advanced 3D spheroid and tumoroid models to evaluate ADC mechanism of action.

What in vivo models are available for ADC efficacy studies?

Our in vivo models include patient-derived xenografts (PDX), syngeneic, and humanized models, along with pharmacokinetics (PK) assessments to quantify ADC exposure and performance.

Resources

Explore Resources for ADC
Development and Discovery

Access whitepapers, posters, and case studies on the use of organoids, PDX models, and functional
assays for ADC development.

ADCs
The Role of Organoids in Antibody-Drug Conjugate Development
Antibody-drug conjugates (ADCs) offer a potentially revolutionary advance in targeted cancer therapy as they combine antibodies and potent cytotoxic...
Learn More

Partner With Crown Bioscience for ADC Development

Connect with our experts to accelerate your ADC program with organoid, PDX, and assay platforms.

Contact Us